Table 1 Clinical characteristics of TCGA, GSE14520 and Guilin cohorts
| TCGA (93) | GSE14520 (224) | Guilin cohort (22) | |
|---|---|---|---|
| Survival state | |||
| Dead | 18 (19.4%) | 86 (38.4%) | 19 (86.4%) |
| Alive | 75 (80.6%) | 138 (61.6%) | 3 (13.6%) |
| Age | |||
| < 65 | 70 (75.3%) | 199 (88.8%) | 20 (90.9%) |
| > = 65 | 23 (24.7%) | 25 (11.2%) | 2 (9.1%) |
| Gender | |||
| Female | 15 (16.1%) | 29 (12.9%) | 0 |
| Male | 78 (83.9%) | 195 (87.1%) | 22 (100%) |
| TNM stage | |||
| I + II | 84 (90.3%) | 174 (77.7%) | 4 (18.2%) |
| III + IV | 9 (9.7%) | 50 (22.3%) | 18 (81.8%) |
| Metastasis Signature | |||
| YES | none | 108 (48.2%) | 11 (50%) |
| NO | 116 (51.8%) | 11 (50%) | |